Citigroup Forecasts Strong Price Appreciation for Qiagen (NYSE:QGEN) Stock

Qiagen (NYSE:QGEN) had its target price increased by research analysts at Citigroup from $45.00 to $52.00 in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage presently has a “hold” rating on the stock. Citigroup‘s price objective suggests a potential upside of 3.25% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Stifel Nicolaus set a $40.00 price objective on Qiagen in a report on Friday, August 7th. Morgan Stanley reissued an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. TD Cowen reissued a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Robert W. Baird raised their price objective on Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 22nd. Finally, Barclays set a $40.00 price objective on Qiagen and gave the company an “equal weight” rating in a report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $45.01.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $50.36 on Monday. The stock has a market cap of $10.38 billion, a price-to-earnings ratio of 25.81, a P/E/G ratio of 5.01 and a beta of 0.61. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The stock’s 50-day moving average is $44.58 and its 200 day moving average is $42.70.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. Qiagen’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, sell-side analysts anticipate that Qiagen will post 2.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently bought and sold shares of the stock. Amundi increased its stake in Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after purchasing an additional 524,959 shares during the period. State Street Corp increased its stake in Qiagen by 4.5% in the 2nd quarter. State Street Corp now owns 2,183,206 shares of the company’s stock worth $85,363,000 after purchasing an additional 93,575 shares during the period. Dimensional Fund Advisors LP increased its stake in Qiagen by 20.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock worth $66,649,000 after purchasing an additional 286,665 shares during the period. Swiss National Bank increased its stake in Qiagen by 21.1% in the 1st quarter. Swiss National Bank now owns 716,059 shares of the company’s stock worth $28,686,000 after purchasing an additional 124,920 shares during the period. Finally, Arbejdsmarkedets Tillaegspension increased its stake in Qiagen by 24.8% in the 1st quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company’s stock worth $25,502,000 after purchasing an additional 126,405 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.